Welcome to our dedicated page for Neuberger Berman High Yield Strategies SEC filings (Ticker: NHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering whether Neuberger Berman High Yield Strategies Fund (NHS) can keep covering its monthly payout? Most investors start with the annual report yet soon discover page after page of credit tables and leverage footnotes. Our platform answers those questions in minutes.
Use Stock Titan to jump straight to what matters in every NHS filing. From the N-CSR that details distribution coverage to the 8-K material events explained, our AI-powered summaries translate technical language into plain English. You’ll see credit-rating shifts, leverage-cost trends and portfolio turnover without reading the entire document.
Need the latest moves by portfolio managers? The Neuberger Berman High Yield Strategies Fund insider trading Form 4 transactions feed shows executive stock trades as they hit EDGAR. Curious about quarterly results? The NHS quarterly earnings report 10-Q filing is parsed instantly, highlighting net investment income and unrealized gains. Our coverage spans every form:
- NHS executive stock transactions Form 4 (real-time alerts)
- NHS annual report 10-K simplified with AI commentary
- Current reports—NHS 8-K material events explained
- Proxy statement for NHS executive compensation
Each document arrives on Stock Titan seconds after EDGAR posts. Our expert analysis layers context, compares past periods and flags red-line changes. Whether you’re monitoring high-yield credit exposure, tracking distribution sustainability, or simply looking for understanding NHS SEC documents with AI, this is your single stop.
Neuberger Berman High Yield Strategies Fund Inc. (NHS) received an amended Schedule 13G filing (Amendment No. 9) from First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation disclosing beneficial ownership of 5,463,038 common shares, representing 21.07% of the class, as of 09/30/2025.
The filing lists 0 shares with sole voting power and 0 shares with shared voting power, and 5,463,038 shares with shared dispositive power. The shares are held primarily across unit investment trusts and accounts associated with First Trust; voting for UIT-held shares is conducted by the trustee to mirror unaffiliated holders. The reporting persons state the position is held in the ordinary course of business and not for the purpose of changing or influencing control, and they disclaim beneficial ownership.
Form 4 highlights: On 07/17/2025, portfolio manager Chris Kocinski purchased 6,000 common shares of Neuberger Berman High Yield Strategies Fund Inc. (NHS) at a volume-weighted average price of $7.3995 (price range $7.395-$7.41). This was an open-market “P” code transaction and no shares were sold.
Following the trade, Kocinski’s direct beneficial ownership rose to 21,000 shares. No derivative securities were involved and there were no amendments to prior filings. The transaction suggests incremental insider confidence but represents a modest dollar amount (~$44k) relative to the fund’s market capitalization.
FAQ
What is the current stock price of Neuberger Berman High Yield Strategies (NHS)?
What is the market cap of Neuberger Berman High Yield Strategies (NHS)?
